Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway

Journal of Nutritional Biochemistry

Volumn 24, Issue 11, 2013, Pages 1823-1829

  Chen, Ming liang ^a   Yi, Long ^a   Jin, Xin ^a   Xie, Qi ^a   Zhang, Ting ^a   Zhou, Xi ^a   Chang, Hui ^a   Fu, Yu jie ^a   Zhu, Jun dong ^a   Zhang, Qian yong ^a   Mi, Man tian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Resveratrol; Sodium dependent glucose transporter; Transmembrane transport; Vascular endothelial cells

Indexed keywords

GLUCOSE; PHLORIZIN; PLASMA PROTEIN; RESVERATROL; SODIUM GLUCOSE COTRANSPORTER 1;

ARTICLE; BLOOD VESSEL; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; UMBILICAL VEIN ENDOTHELIAL CELL;

RATTUS;

AS; ATHEROSCLEROSIS; BOVINE SERUM ALBUMIN; BSA; CLSM; CONFOCAL LASER SCANNING MICROSCOPY; DIMETHYL SULFOXIDE; DMSO; FBS; FETAL BOVINE SERUM; FITC; FLUORESCEIN ISOTHIOCYANATE; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL; HUVEC; LC/MS; LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY; MRM; MULTIPLE REACTION MONITORING; PBS; PHOSPHATE-BUFFERED SALINE; RESVERATROL; SGLT1; SILENT MATING TYPE INFORMATION REGULATION 2 HOMOLOG 1; SIRT1; SODIUM-DEPENDENT GLUCOSE TRANSPORTER; SODIUM-DEPENDENT GLUCOSE TRANSPORTER 1; TRANSMEMBRANE TRANSPORT; VASCULAR ENDOTHELIAL CELLS;

ANIMALS; DIFFUSION; ENDOTHELIAL CELLS; FEMALE; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PHLORHIZIN; RATS; SODIUM-GLUCOSE TRANSPORTER 1; STILBENES; TRANSFECTION;

EID: 84885852033     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.04.003     Document Type: Article

References (31)

1. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
2. Wang Z., Zou J., Cao K., Hsieh T.C., Huang Y., Wu J.M. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med 2005, 16:533-540.
3. Xu Q., Si L.Y. Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action. Nutr Res 2012, 32:648-658.
4. Csiszar A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann N Y Acad Sci 2011, 1215:117-122.
5. Nicholson S.K., Tucker G.A., Brameld J.M. Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc Nutr Soc 2008, 67:42-47.
6. Wu J.M., Hsieh T.C. Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 2011, 1215:16-21.
7. Subramanian L., Youssef S., Bhattacharya S., Kenealey J., Polans A.S., van Ginkel P.R. Resveratrol: challenges in translation to the clinic - a critical discussion. Clin Cancer Res 2010, 16:5942-5948.
8. Asensi M., Medina I., Ortega A., Carretero J., Bano M.C., Obrador E., et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002, 33:387-398.
9. Bertelli A., Bertelli A.A., Gozzini A., Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998, 24:133-138.
10. Soleas G.J., Angelini M., Grass L., Diamandis E.P., Goldberg D.M. Absorption of trans-resveratrol in rats. Methods Enzymol 2001, 335:145-154.
11. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377-1382.
12. Lancon A., Delmas D., Osman H., Thenot J.P., Jannin B., Latruffe N. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 2004, 316:1132-1137.
13. Henry C., Vitrac X., Decendit A., Ennamany R., Krisa S., Merillon J.M. Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells. J Agric Food Chem 2005, 53:798-803.
14. Zorzano A., Sevilla L., Camps M., Becker C., Meyer J., Kammermeier H., et al. Regulation of glucose transport, and glucose transporters expression and trafficking in the heart: studies in cardiac myocytes. Am J Cardiol 1997, 80:65A-76A.
15. Banerjee S.K., McGaffin K.R., Pastor-Soler N.M., Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 2009, 84:111-118.
16. Chen C.Y., Yi L., Jin X., Mi M.T., Zhang T., Ling W.H., et al. Delphinidin attenuates stress injury induced by oxidized low-density lipoprotein in human umbilical vein endothelial cells. Chem Biol Interact 2010, 183:105-112.
17. Juan M.E., Lamuela-Raventos R.M., de la Torre-Boronat M.C., Planas J.M. Determination of trans-resveratrol in plasma by HPLC. Anal Chem 1999, 71:747-750.
18. Biasutto L., Marotta E., Garbisa S., Zoratti M., Paradisi C. Determination of quercetin and resveratrol in whole blood - implications for bioavailability studies. Molecules 2010, 15:6570-6579.
19. Vitaglione P., Ottanelli B., Milani S., Morisco F., Caporaso N., Fogliano V. Dietary trans-resveratrol bioavailability and effect on CCl4-induced liver lipid peroxidation. J Gastroenterol Hepatol 2009, 24:618-622.
20. Ha E., Yim S.V., Jung K.H., Yoon S.H., Zheng L.T., Kim M.J., et al. Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells. Pharmacogenomics J 2006, 6:327-332.
21. Chen C.Y., Yi L., Jin X., Zhang T., Fu Y.J., Zhu J.D., et al. Inhibitory effect of delphinidin on monocyte-endothelial cell adhesion induced by oxidized low-density lipoprotein via ROS/p38MAPK/NF-kappa B pathway. Cell Biochem Biophys 2011, 61:337-348.
22. +, d-glucose cotransporter. A model. Biochim Biophys Acta 1982, 688:557-571.
23. Pervaiz S., Holme A.L. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009, 11:2851-2897.
24. Kelly G.S. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev 2010, 15:313-328.
25. Jiang Y.L. Design, synthesis and spectroscopic studies of resveratrol aliphatic acid ligands of human serum albumin. Bioorg Med Chem 2008, 16:6406-6414.
26. Jannin B., Menzel M., Berlot J.P., Delmas D., Lancon A., Latruffe N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 2004, 68:1113-1118.
27. Van Nieuwenhoven F.A., Van der Vusse G.J., Glatz J.F. Membrane-associated and cytoplasmic fatty acid-binding proteins. Lipids 1996, 31(Suppl):S223-S227.
28. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
29. Muro S., Koval M., Muzykantov V. Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol 2004, 2:281-299.
30. Walgren R.A., Lin J.T., Kinne R.K., Walle T. Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1. J Pharmacol Exp Ther 2000, 294:837-843.
31. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003, 36:79-87.